Adult AML Protocols Could Improve Young Adult Survival

A 2026 study suggests young adults with AML may have better survival outcomes when using adult rather than pediatric protocols.

Updated on Oct. 21, 2026 in Cancer

Isometric editorial illustration showing organized glass laboratory vials, representing clinical treatment protocols for medical research. — A 2026 study indicates that young adults with AML may achieve significantly higher five-year survival rates when treated using adult clinical protocols. AI Illustration. Upload story photo >

A 2026 study suggests that young adults aged 14 to 29 with acute myeloid leukemia (AML) may have improved survival outcomes when treated with adult, rather than pediatric, clinical protocols. The retrospective analysis found significant differences in five-year survival rates depending on the treatment approach used.

Why it matters

Choosing between adult and pediatric protocols is a critical clinical decision for young adults with AML, as these findings suggest that adult-style regimens may offer superior survival benefits for this specific age group. This retrospective data helps physicians refine treatment pathways to potentially improve long-term outcomes for adolescents and young adults.

This retrospective study of 81 patients aged 14 to 29 compared adult and pediatric AML treatment protocols. Findings showed a 77.9% five-year overall survival rate for those on the adult protocol versus 56.7% for those on the pediatric protocol, though these preliminary findings require further confirmation.

The players

Memorial Sloan Kettering Cancer Center

A comprehensive cancer research institution that served as the site for this retrospective study on AML outcomes.

The details

The adult protocol utilized induction therapy consisting of one cycle of cytarabine plus daunorubicin, with reinduction if partial remission was achieved. In contrast, the pediatric protocol involved two cycles of cytarabine plus daunorubicin and etoposide induction, which could include gemtuzumab ozogamicin, bortezomib, or an FLT3 inhibitor. The difference in survival was particularly pronounced among patients who underwent allogeneic hematopoietic stem cell transplantation, where the adult cohort reached a 78.6% survival rate compared to 43.6% in the pediatric group.

Patients in the study were diagnosed between 2010 and 2025.
The study findings were published in 2026.

Health Landscape

Research at Memorial Sloan Kettering Cancer Center continues to examine how age-specific care models impact long-term prognosis for cancers like AML. This study contributes to a shifting standard of care that prioritizes protocol selection based on physiological response rather than age alone.

If you or a loved one are an adolescent or young adult diagnosed with AML, discuss with your oncology team whether an adult or pediatric treatment protocol is better suited for your specific clinical profile. Understanding the rationale behind chosen induction cycles and transplant pathways is a key step in navigating your care plan.

The takeaway

The study underscores that treatment protocol selection can significantly influence survival for young adults with AML. Patients and families should have an open conversation with their hematologist or oncologist about the potential benefits of different induction regimens based on their specific health markers.